Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE
Issued Date
2025-01-01
Resource Type
ISSN
17451981
eISSN
17404398
Scopus ID
2-s2.0-105024543636
Journal Title
Drugs in Context
Volume
14
Rights Holder(s)
SCOPUS
Bibliographic Citation
Drugs in Context Vol.14 (2025)
Suggested Citation
Tran N.T., Lerksaipheng P., Sutcharitchan P., Rojnuckarin P., Yamada K.I., Morales N.P., Luechapudiporn R. Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE. Drugs in Context Vol.14 (2025). doi:10.7573/dic.2025-7-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113587
Title
Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Oxidative modifications of low-density lipoproteins (LDL) have been reported in patients with β-thalassaemia/haemoglobin E (HbE) and are related to cardiovascular complications. Deferiprone (L1) is an iron chelator that decreases iron overload and, consequently, reduces oxidative stress. This study assesses the protective effect of L1 on the oxidative status of LDL in patients with β-thalassaemia/HbE. Methods: Twenty-nine patients with β-thalassaemia/HbE treated with L1 were recruited. The study included a 4-week washout period followed by 4 and 12 weeks of L1 treatment. Non-transferrin-bound iron (NTBI) levels and oxidative stress markers, including thiobarbituric acid reactive substances and α-tocopherol, were monitored at each visit. The rate and content of lipid radical formation following Cu<sup>2+</sup>-induced LDL oxidation in vitro were detected by NBD-Pen, a specific fluorescence probe. Results: L1 was shown to prevent the depletion of α-tocopherol, decrease thiobarbituric acid reactive substances and preserve the levels of lipid components in LDL. A negative correlation between serum NTBI and LDL α-tocopherol indicated that the circulating non-redox-active NTBI can lead to the depletion of α-tocopherol. LDL from the washout period showed the highest oxidative susceptibility when evaluated by NBD-Pen. Conclusion: Iron chelation therapy with L1 improves the oxidative status of LDL in patients with β-thalassaemia/HbE.